Literature DB >> 18277139

The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII.

Natalya M Ananyeva1, Yevgen M Makogonenko, Diana V Kouiavskaia, Jose Ruiz, Vincent Limburg, Alexander B Meijer, Alexey V Khrenov, Midori Shima, Dudley K Strickland, Evgueni L Saenko.   

Abstract

Coagulation factor VIII (FVIII) is a ligand for two members of the low-density lipoprotein receptor family, low-density lipoprotein receptor-related protein (LRP) and low-density lipoprotein receptor, which cooperate in regulating clearance of FVIII from the circulation. This study was aimed to explore the mechanism of interaction of FVIII with very low density lipoprotein receptor (VLDLR), another member of the family, and map receptor-binding sites. Binding of plasma-derived FVIII and its fragments to recombinant soluble ectodomain of VLDLR (sVLDLR) was studied in solid-phase and surface plasmon resonance assays. Full-length FVIII and its light chain bound to sVLDLR with similar affinities (KD = 114 +/- 14 and 95 +/- 11 nmol/l, respectively); in contrast, exposure of high-affinity VLDLR-binding site within the heavy chain (KD = 30 +/- 2 nmol/l) required proteolytic cleavage by thrombin. The VLDLR-binding sites within heavy and light chains were mapped to the A2 domain residues 484-509 and the A3-C1 fragment, based on the inhibitory effects of anti-A2 monoclonal antibody 413 and anti-A3-C1 antibody fragment scFv KM33, respectively, previously shown to inhibit FVIII/LRP interaction. Soluble ligand-binding fragment of VLDLR inhibited activation of factor X by the intrinsic Xase in purified system. In cell culture, a higher Xase activity was associated with wild-type human embryonic kidney cells compared with transfected cells that express VLDLR on the cell surface. We conclude that the binding sites for VLDLR and LRP within FVIII overlap and the A2 site becomes exposed upon physiological activation of FVIII. A functional role of FVIII/VLDLR interaction may be related to regulation of intrinsic Xase activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277139     DOI: 10.1097/MBC.0b013e3282f5457b

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.

Authors:  James H Kurasawa; Svetlana A Shestopal; Elena Karnaukhova; Evi B Struble; Timothy K Lee; Andrey G Sarafanov
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

2.  Lack of association of common polymorphism of LRP1 gene with myocardial infarction in a Chinese Han population.

Authors:  Honggang Ren; Tao Guo; Huafang Wang; Chunyan Sun; Xiaoping Zhang; Heng Mei; Yu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

3.  The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction.

Authors:  Jeanna C Perman; Pontus Boström; Malin Lindbom; Ulf Lidberg; Marcus StÅhlman; Daniel Hägg; Henrik Lindskog; Margareta Scharin Täng; Elmir Omerovic; Lillemor Mattsson Hultén; Anders Jeppsson; Petur Petursson; Johan Herlitz; Gunilla Olivecrona; Dudley K Strickland; Kim Ekroos; Sven-Olof Olofsson; Jan Borén
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

4.  The very low density lipoprotein receptor attenuates house dust mite-induced airway inflammation by suppressing dendritic cell-mediated adaptive immune responses.

Authors:  Karin Fredriksson; Amarjit Mishra; Jonathan K Lam; Elizabeth M Mushaben; Rosemarie A Cuento; Katharine S Meyer; Xianglan Yao; Karen J Keeran; Gayle Z Nugent; Xuan Qu; Zu-Xi Yu; Yanqin Yang; Nalini Raghavachari; Pradeep K Dagur; J Philip McCoy; Stewart J Levine
Journal:  J Immunol       Date:  2014-04-14       Impact factor: 5.422

5.  Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2014-04-02       Impact factor: 3.534

6.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.